Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
US10570196B2 · kind B2 · utility
2Cited by
0References
13Claims
0Family size
Inventors
Key dates
| Filing date | Jul 12, 2017 |
| Grant date | Feb 25, 2020 |
| Priority date | — |
| Expiry date | Jul 12, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides methods of treating tauopathies (e.g. Alzheimer's disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia with Parkinsonism linked to chromosome 17, Pick's Disease, Progressive Supranuclear Palsy, Dementia Pugilistica, Down's Syndrome and others) by administering humanized antibodies. The disclosure also provides the anti-tau humanized antibodies that bind the N-terminal region of tau and also bind to pathological tau aggregates, conformational epitopes and peptides mimicking these epitopes (mimotopes).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.